| Literature DB >> 34799577 |
Joseph Mitchell1, Manju Purohit2,3, Chris P Jewell4, Jonathan M Read4, Gaetano Marrone1, Vishal Diwan1,5, Cecilia Stålsby Lundborg1.
Abstract
Bacterial antibiotic resistance is an important global health threat and the interfaces of antibiotic resistance between humans, animals and the environment are complex. We aimed to determine the associations and overtime trends of antibiotic resistance between humans, animals and water sources from the same area and time and estimate attribution of the other sources to cases of human antibiotic resistance. A total of 125 children (aged 1-3 years old) had stool samples analysed for antibiotic-resistant bacteria at seven time points over two years, with simultaneous collection of samples of animal stools and water sources in a rural Indian community. Newey-West regression models were used to calculate temporal associations, the source with the most statistically significant relationships was household drinking water. This is supported by use of SourceR attribution modelling, that estimated the mean attribution of cases of antibiotic resistance in the children from animals, household drinking water and wastewater, at each time point and location, to be 12.6% (95% CI 4.4-20.9%), 12.1% (CI 3.4-20.7%) and 10.3% (CI 3.2-17.3%) respectively. This underlines the importance of the 'one health' concept and requires further research. Also, most of the significant trends over time were negative, suggesting a possible generalised improvement locally.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34799577 PMCID: PMC8604955 DOI: 10.1038/s41598-021-01174-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Temporal associations between the proportion of resistance to antibiotics in children aged 1–3 years old and that of animals, household water, source drinking water and wastewater within the same community.
| Antibiotics | Animal | Household water | Source drinking water | Wastewater | ||||
|---|---|---|---|---|---|---|---|---|
| Regression coefficient (95% CI) | Regression coefficient (95% CI) | Regression coefficient (95% CI) | Regression coefficient (95% CI) | |||||
| Ampicillin | ||||||||
| Cefotaxime | 6.41 (−126.60 to 139.43) | 0.906 | −3.58 (−58.07 to 50.91) | 0.872 | − | |||
| Ceftazidime | −6.15 (−129.58 to 117.29) | 0.903 | 225.84 (−180.89 to 632.57) | 0.213 | −6.36 (−65.19 to 52.47) | 0.792 | −13.05 (−31.69 to 5.59) | 0.132 |
| Cefepime | 245.82 (−54.20 to 545.83) | 0.089 | 56.75 (−30.59 to 144.09) | 0.156 | 56.45 (−15.65 to 128.55) | 0.100 | ||
| Nalidixic acid | − | 63.50 (−20.52 to 147.52) | 0.110 | 6.26 (−23.51 to 36.03) | 0.612 | 4.74 (−30.78 to 40.27) | 0.745 | |
| Ciprofloxacin | −106.28 (−232.01 to 19.44) | 0.082 | 56.94 (−3.33 to 117.20) | 0.059 | −4.35 (−106.35 to 97.85) | 0.919 | −11.35 (63.92 to 41.23) | 0.603 |
| Nitrofurantoin | 15.03 (−36.95 to 67.01) | 0.491 | 31.88 (−17.64 to 81.40) | 0.159 | −4.63 (−27.56 to 18.30) | 0.626 | −1.56 (−91.20 to 88.08) | 0.966 |
| Gentamicin | 19.42 (−85.78 to 124.62) | 0.655 | 11.19 (−58.84 to 81.22) | 0.698 | 2.20 (−14.98 to 19.38) | 0.755 | 34.24 (−32.53 to 101.01) | 0.245 |
| Amikacin | 48.48 (−38.95 to 135.91) | 0.213 | 29.86 (−45.76 to 105.49) | 0.357 | 2.61 (−11.13 to 16.35) | 0.646 | 5.71 (−117.25 to 128.68) | 0.910 |
| Tetracycline | −21.36 (−122.28 to 79.56) | 0.610 | 4.72 (−15.15 to 24.58) | 0.568 | 41.35 (−18.82 to 101.53) | 0.138 | ||
| Tigecycline | −5.34 (−28.67 to 17.99) | 0.582 | −17.43 (−50.08 to 15.22) | 0.228 | 0.91 (−2.99 to 4.82) | 0.573 | ||
| Imipenem | ||||||||
| Meropenem | −217.62 (−471.84 to 36.59) | 0.079 | 121.83 (−104.19 to 347.85) | 0.224 | 1.37 (−29.15 to 31.89) | 0.913 | 18.08 (−16.52 to 52.67) | 0.237 |
| Co- trimoxazole | −80.23 (−240.44 to 79.98) | 0.254 | 96.96 (−21.64 to 215.57) | 0.090 | −26.31 (−103.57 to 50.95) | 0.421 | − | |
| Sulphamethiazole | −36.31 (−97.60 to 24.97) | 0.188 | −19.14 (−57.11 to 18.83) | 0.252 | −15.48 (−47.64 to 16.67) | 0.271 | ||
| Colistin | N/A (N/A) | N/A | −4.72 (−55.54 to 46.09) | 0.447 | N/A (N/A) | N/A | N/A (N/A) | N/A |
| ESBL | −63.78 (−204.33 to 76.78) | 0.296 | 15.58 (−35.07 to 66.22) | 0.465 | −10.85 (−47.29 to 25.60) | 0.479 | ||
| MDR | −35.11 (−164.73 to 94.50) | 0.517 | −26.92 (−58.58 to 4.75) | 0.081 | −35.87 (78.26 to 6.53) | 0.082 | ||
ESBL extended spectrum beta lactamase, MDR multi drug resistant.
Bold text indicates statistical significance (p-value <0.05).
Figure 1Violin Plot of the proportion of Human Cases Attributable to Each Environmental Source. The bold horizontal line for each source represents the mean for each source. The bold horizontal line for each source represents the mean for each source. HDW Household Drinking Water, SDW Source Drinking Water.
Figure 2Violin Plot of the proportion of Human Cases Attributable to Each Environmental Source. The bold horizontal line for each source represents the mean for each source. HDW Household Drinking Water, SDW Source Drinking Water.
Temporal trends of antibiotic resistance detected in humans, animals, household drinking water, source drinking water and wastewater, for each antibiotic.
| Antibiotics | Human | Animal | Household drinking water | Source drinking water | Wastewater | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Regression coefficient (95% CI) | Regression coefficient (95% CI) | Regression coefficient (95% CI) | Regression coefficient (95% CI) | Regression coefficient (95% CI) | ||||||
| Ampicillin | 5.32 (−0.08 to 10.71) | 0.052 | 3.64 (−3.56 to 10.84) | 0.250 | 4.30 (−3.37 to 11.97) | 0.209 | ||||
| Cefotaxime | −0.57 (−2.86 to 1.71) | 0.547 | 0.17 (−1.48 to 1.82) | 0.802 | −0.90 (−1.92 to 0.13) | 0.075 | − | 0.33 (−4.78 to 5.43) | 0.875 | |
| Ceftazidime | 0.46 (−2.21 to 3.13) | 0.677 | 0.84 (−1.02 to 2.71) | 0.297 | −0.02 (−0.33 to 0.29) | 0.881 | −3.49 (−6.98 to 0.01) | 0.050 | 0.97 (4.11 to 6.06) | 0.643 |
| Cefepime | 2.32 (−3.13 to 7.77) | 0.324 | 0.46 (−2.38 to 3.30) | 0.696 | −1.03 (−7.52 to 5.47) | 0.701 | 2.63 (−2.01 to 7.27) | 0.205 | ||
| Nalidixic acid | −0.46 (−2.49 to 1.58) | 0.588 | 0.61 (−1.46 to 2.67) | 0.482 | −0.76 (−1.83 to 0.31) | 0.129 | − | − | ||
| Ciprofloxacin | 0.39 (−2.18 to 2.96) | 0.711 | −0.52 (−1.86 to 0.81) | 0.355 | −0.96 (−1.94 to 0.02) | 0.054 | − | − | ||
| Nitrofurantoin | −0.38 (−1.03 to 0.27) | 0.191 | −0.91 (−2.08 to 0.26) | 0.103 | 0.09 (−1.77 to 1.95) | 0.906 | −0.52 (−2.34 to 1.30) | 0.493 | 0.48 (−0.29 to 1.24) | 0.172 |
| Gentamicin | −0.22 (−0.61 to 0.17) | 0.206 | − | − | −0.11 (−1.35 to 1.14) | 0.837 | − | |||
| Amikacin | −0.18 (−0.61 to 0.24) | 0.320 | −0.95 (−3.07 to 1.18) | 0.304 | 0.28 (−0.17 to 0.72) | 0.172 | ||||
| Tetracycline | −0.17 (−1.87 to 1.53) | 0.805 | −0.57 (−2.05 to 0.92) | 0.372 | − | − | −1.37 (−3.44 to 0.69) | 0.148 | ||
| Tigecycline | −0.02 (−0.08 to 0.04) | 0.434 | 0.05 (−0.39 to 0.49) | 0.780 | −0.07 (−0.20 to 0.05) | 0.186 | −1.27 (−2.55 to 0.01) | 0.051 | − | |
| Imipenem | −0.05 (−5.30 to 5.20) | 0.980 | −0.84 (−6.32 to 4.64) | 0.710 | −0.15 (−4.76 to 4.46) | 0.937 | −1.30 (−7.00 to 4.36) | 0.581 | −0.46 (−4.89 to 3.98) | 0.802 |
| Meropenem | 1.22 (−1.74 to 4.19) | 0.337 | −0.32 (−1.08 to 0.43) | 0.319 | −0.38 (−1.89 to 1.13) | 0.543 | − | −1.35 (−3.65 to 0.96) | 0.193 | |
| Co-trimoxazole | 1.06 (−0.51 to 2.63) | 0.144 | −0.14 (−1.02 to 0.73) | 0.688 | 0.12 (−0.87 to 1.10) | 0.773 | −0.77 (−2.04 to 0.49) | 0.177 | −0.71 (−3.16 to 1.73) | 0.487 |
| Sulphamethiazole | 0.23 (−1.79 to 2.24) | 0.785 | − | −0.74 (−2.27 to 0.78) | 0.266 | −2.73 (−6.88 to 1.43) | 0.153 | − | ||
| Colistin | 0.07 (−0.16 to 0.29) | 0.167 | N/A (N/A) | N/A | −0.47 (−4.44 to 3.51) | 0.375 | N/A (N/A) | N/A | N/A (N/A) | N/A |
| ESBL | − | 0.92 (−0.37 to 2.20) | 0.126 | − | − | −0.65 (−5.05 to 3.75) | 0.719 | |||
| MDR | 1.22 (−1.07 to 3.50) | 0.229 | 0.08 (−2.66 to 2.83) | 0.940 | −0.47 (−1.76 to 0.83) | 0.398 | − | −0.70 (−4.56 to 3.16) | 0.661 | |
ESBL extended spectrum beta lactamase, MDR multi drug resistant.
Bold text indicates statistical significance (p-value <0.05).
Figure 3Line graph of over time trend of percentage of resistance to ampicillin, with regression coefficients and p-value for Newey–West analyses. RC Regression Coefficient p = p-value.
Figure 4Line graph of over time trend of percentage of production of ESBL, with regression coefficients and p-value for Newey–West analyses. RC Regression Coefficient p = p-value.